Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

BIOLOGICAL5 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, Sanofi

Conditions

Healthy VolunteersMeningitisMeningococcal ImmunisationMeningococcal Immunisation (Healthy Volunteers)Meningococcal InfectionsMeningococcal Meningitis

Phase 3

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

CompletedNCT02752906

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-04-15End: 2016-12-19Updated: 2022-04-05

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

CompletedNCT04368429

SanofiMeningococcal Immunisation (Healthy Volunteers)

Start: 2020-05-22End: 2020-11-07Updated: 2025-09-15

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

CompletedNCT05794230

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunisation

Start: 2023-03-27End: 2025-11-15Updated: 2026-01-21

Phase 4

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

CompletedNCT02864927

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-07-21End: 2019-06-12Updated: 2022-04-25

Unknown Phase

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

CompletedNCT02699840

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections, Meningococcal Meningitis

Start: 2016-02-29End: 2016-07-25Updated: 2022-04-25

Related Papers

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study

Japanese Journal of Infectious Diseases2023-01-301 citations

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan

Open Forum Infectious Diseases2021-11-01

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra®) in the Republic of Korea, 2014–2019

Infectious Diseases and Therapy2021-01-137 citations

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study

Human Vaccines & Immunotherapeutics2020-03-2530 citations

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults

Open Forum Infectious Diseases2019-10-011 citations